PIK1 Antibody

What is PIK1 and what cellular functions does it regulate?

PIK1 (Phosphatidylinositol 4-kinase) is an essential enzyme involved in cellular processes including signaling pathways and membrane trafficking. In Schizosaccharomyces pombe (fission yeast), Pik1 kinase activity is required for septation, a critical process during cell division. The protein contains functional domains that facilitate protein-protein interactions, with the R838 residue being particularly important for interactions with binding partners such as Cdc4 . Unlike the similarly named but distinct protein PICK1 (Protein Interacting with C Kinase 1), which functions as an adapter protein organizing subcellular localization of membrane proteins containing PDZ recognition sequences, PIK1 has unique catalytic activity and cellular roles .

What detection methods are most suitable for PIK1 in experimental systems?

For detecting PIK1 in experimental systems, several methodological approaches have demonstrated efficacy. Immunoblotting (Western blot) can effectively visualize PIK1 when using appropriate antibodies, with expression systems typically producing a band migrating at approximately 97 kDa . Enzyme-linked immunosorbent assay (ELISA) provides quantitative detection capabilities, particularly when employing sandwich ELISA formats with purified interaction partners such as Cdc4 . For subcellular localization studies, fluorescence techniques such as expression of GFP-tagged PIK1 constructs or indirect immunofluorescence with specific anti-PIK1 antisera can reveal distribution patterns, including punctate cytoplasmic localization and occasional enrichment at the medial region during specific cell cycle phases .

How can I differentiate between PIK1 and other similarly named proteins in my experiments?

Distinguishing PIK1 from similarly named proteins (PICK1, PIK3IP1, PINK1) requires careful experimental design:

When analyzing experimental data, verify protein identity through multiple approaches: molecular weight confirmation, reactivity with specific antibodies, subcellular localization patterns, and functional assays relevant to each protein's known activities .

What are the optimal conditions for antibody-based detection of PIK1 in cell lysates?

For optimal antibody-based detection of PIK1 in cell lysates, several methodological considerations are crucial. Sample preparation should include cell lysis under conditions that preserve protein integrity—typically using a French press 'mini' cell (3 passages at 900 p.s.i.) in phosphate-buffered saline (PBS) with protease inhibitors at 4°C . For immunoblot analysis, loading approximately 5 μg of total protein per lane provides detectable signals for PIK1 when expressed under control of derepressed promoters such as nmt1 .

When using PIK1 antibodies, primary antibody dilutions of 1:1000 are typically effective, followed by secondary antibody (goat anti-rabbit IgG-HRP) at 1:5000 dilution . The detection system should be sensitive enough to visualize the ~97 kDa PIK1 band, distinguishing it from background bands (such as the commonly observed 93 kDa non-specific band) . For quantitative analysis, ELISA-based approaches with purified interaction partners coated on multiwell plates provide sensitive detection of PIK1 variants with different binding affinities .

How can I validate PIK1 antibody specificity for my experimental system?

Validating PIK1 antibody specificity requires a multi-faceted approach:

• Genetic controls: Compare antibody reactivity in wild-type samples versus PIK1-depleted or PIK1-null mutant systems. For example, using temperature-degron approaches (pik1-td) provides a conditional system where PIK1 is specifically degraded, serving as a negative control for antibody specificity .

• Expression system validation: Ectopic expression of PIK1 under control of inducible promoters (such as nmt1) allows comparison of signal intensity between repressed and derepressed conditions. Antibody reactivity should correlate with expression levels, showing stronger signals under derepression conditions .

• Mutant variant analysis: Testing antibody reactivity against PIK1 mutants with specific amino acid substitutions (e.g., R838A, D709A) can confirm epitope specificity. If an antibody recognizes all variants with equivalent intensity, this suggests recognition of conserved epitopes .

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related proteins by testing the antibody against purified recombinant proteins or lysates from cells expressing related proteins. Specific antibodies should show minimal reactivity with non-target proteins .

• Application-specific validation: For each experimental technique (immunoblot, ELISA, immunofluorescence), perform independent validation experiments with appropriate positive and negative controls .

What purification methods are most effective for generating PIK1-specific antibodies?

Generating effective PIK1-specific antibodies requires strategic approaches to immunogen design, antibody production, and purification. Based on successful antibody generation projects for related proteins, the following methodology is recommended:

• Immunogen selection: Choose unique regions of PIK1 with low homology to related proteins. For example, using recombinant fragments like GST-fusion proteins containing specific PIK1 domains (similar to the GST-PIK3IP1(62-168) approach) .

• Immunization protocol: Implement a robust immunization schedule in BALB/c mice or rabbits. For monoclonal antibody production, mice are typically preferred due to established hybridoma technology .

• Hybridoma generation and screening: Following cell fusion, implement rigorous screening protocols using ELISA against both the immunizing antigen and full-length PIK1 protein. Secondary screening should include Western blot and additional application-specific tests .

• Antibody purification methods:

  • Protein A/G affinity chromatography for IgG purification from hybridoma supernatants or ascites fluid

  • Antigen-specific affinity chromatography using immobilized PIK1 protein or peptide epitopes

  • Ion exchange chromatography as a polishing step to remove remaining contaminants

• Quality control: Characterize purified antibodies for specificity, sensitivity, and application performance. Determine antibody class/subclass (e.g., IgG1), titer (effective antibodies may reach titers of 1:10⁷), and reactivity patterns in relevant applications .

Recombinant antibody technology, as demonstrated with rabbit monoclonal antibodies, offers advantages for generating highly specific reagents with reproducible performance across production batches .

Why might my PIK1 antibody detect multiple bands in Western blot analysis?

Detection of multiple bands in Western blot analysis when using PIK1 antibodies can result from several experimental or biological factors:

• Non-specific binding: Common non-specific bands may appear, such as the approximately 93 kDa band observed even in negative control samples lacking PIK1 overexpression . This non-specific reactivity persists under both repressed and derepressed conditions and represents a technical artifact rather than PIK1-related signal.

• Post-translational modifications: PIK1 may undergo modifications (phosphorylation, ubiquitination, etc.) that alter electrophoretic mobility, resulting in multiple bands representing modified variants of the same protein.

• Proteolytic degradation: Sample preparation conditions that permit proteolysis may generate PIK1 fragments detected by antibodies recognizing different epitopes. Ensure samples are prepared with appropriate protease inhibitors at 4°C to minimize degradation .

• Alternative splicing: PIK1 may exist as splice variants with different molecular weights. Similar to PIK3IP1, which has variant forms like PIK3IP1-v1 with distinct localization patterns , PIK1 could have functionally relevant isoforms.

• Cross-reactivity with related proteins: Antibodies might recognize related proteins with structural homology to PIK1, particularly if epitopes are in conserved domains.

To resolve these issues, implement additional controls including wild-type versus mutant comparisons, ectopic expression systems with repressible promoters, and peptide competition assays to identify specific versus non-specific signals .

How can I quantitatively assess PIK1-protein interactions using antibody-based techniques?

Quantitative assessment of PIK1-protein interactions can be achieved through several antibody-based approaches:

• Sandwich ELISA:

  • Coat plates with purified interaction partner (e.g., Cdc4)

  • Block wells with appropriate blocker (2% skim milk in PBS)

  • Incubate with serial dilutions of cell lysates containing PIK1 or PIK1 variants

  • Detect bound PIK1 using anti-PIK1 antibodies and HRP-conjugated secondary antibodies

  • Quantify signal using appropriate substrate (e.g., TMB) and measure optical density

  • Generate binding curves for comparative analysis of interaction strengths

• Co-immunoprecipitation with quantitative immunoblotting:

  • Immunoprecipitate PIK1 or interaction partners using specific antibodies

  • Analyze precipitates by immunoblotting with reciprocal antibodies

  • Quantify band intensities using densitometry

  • Calculate molar ratios or relative enrichment compared to input controls

• Proximity ligation assay (PLA):

  • Use primary antibodies against PIK1 and potential interaction partners

  • Apply species-specific secondary antibodies with oligonucleotide probes

  • Quantify interaction signals (fluorescent dots) per cell

  • Compare signal frequency across experimental conditions

• Yeast two-hybrid analysis with β-galactosidase activity measurement:

  • Express PIK1 bait constructs (e.g., full-length, domains, or mutant variants)

  • Express potential interaction partners as prey constructs

  • Quantify interaction strength through β-galactosidase activity assays

  • Compare relative interaction strengths between wild-type and mutant constructs

When analyzing PIK1-protein interactions, the R838 residue warrants particular attention, as mutations at this position (R838A) disrupt interaction with partners like Cdc4, while other mutations (D709A) may not affect or may enhance these interactions .

What controls are essential when analyzing PIK1 phosphorylation status?

When analyzing PIK1 phosphorylation status, implementing comprehensive controls is critical for accurate interpretation:

• Phosphatase treatment controls:

  • Split samples and treat one portion with lambda phosphatase

  • Compare migration patterns and antibody reactivity before and after treatment

  • Loss of signal or mobility shift after phosphatase treatment confirms phosphorylation-specific detection

• Phospho-mimetic and phospho-null mutants:

  • Generate PIK1 variants with mutations at potential phosphorylation sites:

    • Phospho-null mutations (Ser/Thr → Ala)

    • Phospho-mimetic mutations (Ser/Thr → Asp/Glu)

  • Compare antibody reactivity and functional outcomes between variants

• Kinase inhibition/activation:

  • Treat samples with relevant kinase inhibitors or activators

  • Monitor changes in PIK1 phosphorylation status

  • Correlate with functional readouts of PIK1 activity

• Phospho-specific antibody validation:

  • Test antibody reactivity against synthetic phosphorylated and non-phosphorylated peptides

  • Confirm specificity through peptide competition assays

  • Validate with phospho-null mutant proteins as negative controls

• Physiological context controls:

  • Analyze PIK1 phosphorylation across relevant biological conditions:

    • Cell cycle stages (particularly during septation in yeast models)

    • Stress responses

    • Developmental stages

  • Correlate phosphorylation patterns with functional outcomes

Drawing from approaches used with related kinases like PINK1, which phosphorylates ubiquitin at serine 65, methodological considerations should include establishing baseline phosphorylation levels under physiological conditions and implementing ultrasensitive detection methods for low-abundance phosphorylated species .

How can PIK1 antibodies be used to study protein dynamics during cell division?

PIK1 antibodies offer powerful tools for investigating protein dynamics during cell division, particularly in systems where PIK1 functions in septation and cytokinesis:

• Time-resolved immunofluorescence microscopy:

  • Synchronize cells using methods such as temperature-sensitive cdc25-22 mutants

  • Sample at defined intervals after release from cell cycle block

  • Process for immunofluorescence using PIK1-specific antibodies

  • Correlate PIK1 localization patterns with cell cycle markers (nuclear DNA, F-actin rings, septum formation)

  • Quantify the percentage of cells showing medial PIK1 enrichment relative to other cell cycle indices

• Live-cell imaging with fluorescent fusion proteins:

  • Express 2XeGFP-PIK1 fusions under regulated promoters

  • Perform time-lapse microscopy of dividing cells

  • Track dynamic localization changes throughout mitosis and cytokinesis

  • Quantify fluorescence intensity at specific cellular locations over time

  • Correlate with cell cycle progression markers

• Co-localization studies with Golgi markers:

  • Combine PIK1 antibody staining with markers for Golgi compartments (e.g., Gma12p-GFP)

  • Analyze co-localization patterns throughout the cell cycle

  • Determine the relationship between PIK1's Golgi association and its roles in septation

• Quantitative interaction dynamics:

  • Use techniques like Förster resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC)

  • Monitor real-time interaction changes between PIK1 and binding partners during mitosis

  • Correlate interaction dynamics with cell cycle progression and septation events

Research has demonstrated that PIK1 exhibits dynamic localization patterns during cell division, with approximately 8% of cells showing medial fluorescent bands when expressing 2XeGFP-PIK1 fusions . This medial localization correlates with specific phases of cytokinesis, providing insights into PIK1's temporal regulation during cell division.

What approaches can reveal structure-function relationships in PIK1 using antibody-based methods?

Elucidating structure-function relationships in PIK1 through antibody-based methods requires integrated experimental strategies:

• Domain-specific antibody analysis:

  • Generate or obtain antibodies targeting distinct PIK1 domains

  • Compare accessibility of epitopes under different conditions

  • Identify conformational changes that expose or mask specific domains

  • Correlate epitope accessibility with functional states of the protein

• Mutational analysis with functional readouts:

  • Generate PIK1 variants with specific mutations (e.g., R838A, D709A)

  • Analyze protein-protein interactions using quantitative antibody-based methods

  • Correlate interaction changes with functional outcomes

  • Establish structure-function maps of critical residues

• Conditional expression systems combined with functional assays:

  • Express wild-type or mutant PIK1 variants using regulatable promoters

  • Monitor phenotypic outcomes (e.g., septation defects, growth parameters)

  • Correlate protein expression levels (by antibody detection) with functional outcomes

  • Establish dose-response relationships between PIK1 activity and biological functions

• Antibody epitope mapping and accessibility studies:

  • Use antibody panels recognizing different PIK1 epitopes

  • Compare reactivity patterns under various conditions

  • Identify regions subject to conformational changes or interactions

  • Develop structural models incorporating accessibility data

Research demonstrates that specific residues, such as R838 in PIK1, play critical roles in protein-protein interactions. When this residue is mutated to alanine (R838A), interaction with binding partners like Cdc4 is disrupted, despite the mutant protein being expressed at levels comparable to or higher than wild-type PIK1 . These findings illustrate how targeted mutations combined with antibody-based detection can reveal functional domains within PIK1.

How can advanced antibody technologies enhance detection of low-abundance PIK1 in tissue samples?

Detecting low-abundance PIK1 in tissue samples presents significant challenges that can be addressed through advanced antibody technologies:

• Signal amplification systems:

  • Tyramide signal amplification (TSA) can enhance detection sensitivity by 10-100 fold

  • Poly-HRP secondary antibody systems provide enhanced signal without increasing background

  • Rolling circle amplification (RCA) technologies offer exponential signal enhancement for immunohistochemistry

• Ultrasensitive detection platforms:

  • Single molecule array (Simoa) technology for digital detection of proteins at femtomolar concentrations

  • Proximity extension assay (PEA) combining antibody specificity with nucleic acid amplification

  • Mass cytometry (CyTOF) for highly multiplexed analysis with minimal signal overlap

• Enrichment strategies prior to detection:

  • Laser capture microdissection to isolate regions of interest

  • Subcellular fractionation to concentrate PIK1-containing compartments

  • Immunoprecipitation prior to analysis to concentrate target protein

• Recombinant antibody engineering approaches:

  • Development of high-affinity recombinant rabbit monoclonal antibodies

  • Optimization of antibody formats (Fab, scFv) for improved tissue penetration

  • Bispecific antibodies targeting PIK1 and associated proteins for enhanced specificity

Drawing from approaches used for related low-abundance phospho-proteins, physiological levels of PIK1 may be difficult to detect and require ultrasensitive methods. Development of rabbit monoclonal antibodies with high specificity and affinity provides promising tools for detecting physiologically relevant levels of PIK1 and its modified forms in tissue samples .

What are the optimal fixation and permeabilization conditions for PIK1 immunofluorescence studies?

Optimizing fixation and permeabilization conditions is critical for successful PIK1 immunofluorescence studies:

• Fixation methods comparison:

  Fixation Method	Advantages	Limitations	Recommended for PIK1
  Methanol (-20°C)	Good antigen preservation, removes lipids	May cause protein denaturation	Effective for detecting PIK1 co-localization with Golgi markers
  Paraformaldehyde (4%)	Preserves cellular architecture	May mask some epitopes	Suitable with additional permeabilization
  Glutaraldehyde (0.1-0.5%)	Strong fixation for structural studies	High autofluorescence, may over-fix	Not typically recommended for PIK1

• Permeabilization optimization:

  • After paraformaldehyde fixation, permeabilize with 0.1-0.5% Triton X-100

  • For gentle permeabilization, use 0.1-0.2% saponin (reversible, preserves membranes)

  • Digitonin (10-50 μg/ml) provides selective plasma membrane permeabilization

• Antigen retrieval considerations:

  • Heat-induced epitope retrieval may recover masked epitopes after paraformaldehyde fixation

  • Enzymatic retrieval using proteases should be carefully optimized to prevent over-digestion

  • pH-controlled buffers (citrate buffer pH 6.0 or Tris-EDTA pH 9.0) may enhance epitope accessibility

• Blocking optimization:

  • Use 2-5% BSA or 5-10% serum from secondary antibody host species

  • Include 0.1-0.3% Triton X-100 in blocking solution for improved penetration

  • Consider additional blocking with 5% non-fat dry milk for reduced background

Research demonstrates that methanol fixation has been successfully employed for co-localization studies of PIK1 with Golgi-associated markers like Gma12p-GFP . When developing new immunofluorescence protocols, systematic comparison of fixation and permeabilization conditions is recommended to optimize signal-to-noise ratio while preserving relevant subcellular structures.

How should antibody validation be modified for different experimental systems studying PIK1?

Antibody validation strategies must be tailored to specific experimental systems studying PIK1:

• Yeast models (S. pombe):

  • Genetic validation using pik1-null mutants complemented with plasmid-borne wild-type or mutant alleles

  • Temperature-sensitive degron systems (pik1-td) for conditional depletion controls

  • Integration of epitope tags at the genomic locus for antibody validation

  • Careful control for cross-reactivity with related yeast phosphatidylinositol kinases

• Mammalian cell culture systems:

  • CRISPR/Cas9 knockout cell lines as negative controls

  • siRNA/shRNA knockdown with titrated depletion efficiency

  • Ectopic expression systems with inducible promoters

  • Characterization using multiple detection methods (immunoblot, immunofluorescence, flow cytometry)

• Tissue samples:

  • Peptide competition assays to verify specificity

  • Comparison of multiple antibody clones targeting different epitopes

  • Correlation with mRNA expression data from matched samples

  • Species-specific validation when working across evolutionary boundaries

• In vitro biochemical assays:

  • Recombinant protein controls with known concentrations

  • Antibody affinity and specificity determination using surface plasmon resonance

  • Cross-reactivity assessment against related protein family members

  • Epitope mapping to confirm recognition sites

• System-specific considerations:

  • Validate antibodies separately for each application (WB, IF, IP, ELISA)

  • Determine optimal working concentrations empirically for each system

  • Document lot-to-lot variation through standardized validation protocols

  • Consider post-translational modifications that may affect epitope recognition

When working with PIK1 in yeast systems, approaches like sandwich ELISA using purified interaction partners (e.g., Cdc4) have proven effective for validating antibody specificity and analyzing protein-protein interactions . For any experimental system, validation should include both positive and negative controls that are appropriate for the specific biological context.

What are the latest innovations in PIK1 antibody development for multi-dimensional analysis?

Recent innovations in antibody technology offer advanced capabilities for multi-dimensional analysis of PIK1:

• Multiplexed detection systems:

  • Sequential immunofluorescence with cyclic antibody elution and re-probing

  • Mass cytometry (CyTOF) using metal-conjugated antibodies for highly multiplexed analysis

  • Co-detection by indexing (CODEX) for spatial analysis of dozens of proteins simultaneously

  • Oligonucleotide-conjugated antibodies for high-parameter imaging

• Engineered antibody formats:

  • Bispecific antibodies targeting PIK1 and interaction partners simultaneously

  • Single-domain antibodies (nanobodies) for improved tissue penetration

  • Recombinant rabbit monoclonal antibodies offering superior affinity and specificity

  • Conjugation-ready formats designed for coupling to fluorochromes, metal isotopes, oligonucleotides, or enzymes

• Activity-based probes and sensors:

  • Conformation-specific antibodies that distinguish active versus inactive PIK1 states

  • Proximity-based biosensors combining antibody recognition with reporter systems

  • Antibody-based FRET pairs for detecting PIK1 interactions or conformational changes

  • Intrabodies for tracking PIK1 dynamics in living cells

• Advanced analysis platforms:

  • Imaging mass cytometry for spatial proteomic analysis

  • Digital spatial profiling combining antibody detection with NGS readout

  • AI-assisted image analysis for complex pattern recognition

  • Single-cell western blot technologies for heterogeneity assessment

Drawing from developments in related fields, the generation of recombinant rabbit monoclonal antibodies has produced reagents with high specificity and sensitivity for detecting low-abundance phosphorylated proteins . Similar approaches applied to PIK1 could enable detection of physiologically relevant modifications or conformational states that were previously undetectable with conventional antibody technologies.